[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"preoperative\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:preoperative":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,81,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100603052","phase-2-a-single-arm-multicenter-exploratory-clinical-study-of-tace-combined-with-iparomlimab-and-tuvonralimab-injection-ql1706-and-lenvatinib-for-perioperative-treatment-of-resectable-hepatocellular-carcinoma-100603052",false,"NCT07131501","A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma","A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma (HCC)","Inclusion Criteria:\n\n1. Voluntarily participate, sign ICF, demonstrate good expected compliance, and be willing to cooperate with follow-up.\n2. Age 18-75 years, any gender.\n3. HCC diagnosis confirmed by histopathology, cytology, or imaging.\n4. Resectable HCC staged as CNLC IIb-IIIa (excluding Vp3 and Vp4) or CNLC Ib-IIa with high-risk recurrence factors, confirmed by multidisciplinary liver surgery expert panel.\n5. For CNLC Ib-IIa subjects, presence of at least ONE high-risk recurrence factor.\n6. No prior systemic therapy for HCC (chemotherapy, targeted therapy, immunotherapy, etc.). Subjects with prior curative surgery or ablation are eligible only if recurrence occurred \\>2 years post-resection. Subjects with prior other local therapies are excluded.\n7. Child-Pugh class A.\n8. ECOG PS score 0-1.\n9. Expected survival ≥12 months.\n10. Adequate organ function within 7 days prior to study intervention.\n11. For subjects with HBV infection.\n12. Women of childbearing potential: Must agree to abstinence or use highly effective contraception from ICF signing until ≥120 days after last study drug dose. Negative pregnancy test within 7 days prior to intervention. Not breastfeeding.\n13. Male subjects with WOCBP partners: Must agree to abstinence or use highly effective contraception from ICF signing until ≥120 days after last study drug dose. Must not donate sperm during this period. Males with pregnant partners must use condoms.\n\nExclusion Criteria:\n\n1. Known intrahepatic cholangiocarcinoma, sarcomatoid HCC, mixed carcinoma (\\>30% ICC component), or fibrolamellar carcinoma. Active malignancy other than HCC within 5 years or concurrently. Cured localized cancers are eligible.\n2. Current or history of interstitial lung disease\u002Fpneumonitis requiring steroids, or other active lung disease potentially interfering with immune-related pulmonary toxicity evaluation\u002Fmanagement, or active pneumonia\u002Fsevere impaired pulmonary function on screening CT. Active tuberculosis.\n3. Active autoimmune disease or history of autoimmune disease with potential recurrence. Vitiligo, psoriasis, alopecia not requiring systemic therapy, controlled Type I diabetes on insulin, or childhood asthma resolved in adulthood without intervention are eligible. Asthma requiring bronchodilators is excluded.\n4. Systemic immunosuppressive therapy (\\>10 mg\u002Fday prednisone equivalent) within 2 weeks prior to intervention.\n5. Active infection, unexplained fever ≥38.5°C within 1 week prior, or baseline WBC \\>15 × 10⁹\u002FL. Therapeutic antibiotics (IV\u002Foral) within 2 weeks prior (prophylactic IV antibiotics ≤48h duration allowed).\n6. Primary or acquired immunodeficiency.\n7. Live attenuated vaccine within 4 weeks prior to intervention or anticipated need during study or within 60 days after last Iparomlimab and Tuvonralimab Injection dose.\n8. Significant bleeding symptoms or predisposition within 6 months prior. If baseline fecal occult blood positive, repeat test; if still positive, requires gastroscopy.\n9. Known hereditary\u002Facquired bleeding\u002Fthrombotic diathesis. Current therapeutic-dose anticoagulants\u002Fthrombolytics (prophylactic low-dose aspirin allowed).\n10. Arterial thromboembolic events within 6 months prior.\n11. Poorly controlled cardiac disease.\n12. Hypertension uncontrolled by medication (average SBP ≥140 mmHg or DBP ≥90 mmHg on ≥2 readings). History of hypertensive crisis or encephalopathy.\n13. Major vascular disease within 6 months prior.\n14. Serious unhealed wounds, active ulcers, or untreated fractures.\n15. Major surgery within 4 weeks prior or anticipated major surgery during study.\n16. Inability to swallow pills, malabsorption syndrome, or GI condition affecting absorption.\n17. Bowel obstruction or related symptoms\u002Fsigns within 6 months prior requiring parenteral support\u002Ffeeding. Subjects with prior resolved obstruction treated definitively (surgically) may be eligible after assessment.\n18. Strong CYP3A4 inducers within 2 weeks prior or strong CYP3A4 inhibitors within 1 week prior.\n19. Known hypersensitivity to any study drug or excipient.\n20. Participation in another investigational drug study within 4 weeks prior.\n21. Pregnancy or lactation.\n22. Any other condition deemed unsuitable by the investigator.","ALL","18 Years","75 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a single-arm, multicenter, exploratory clinical study evaluating the efficacy and safety of TACE combined with Iparomlimab and Tuvonralimab Injection (QL1706) and lenvatinib for perioperative treatment of resectable HCC (CNLC IIb-IIIa excluding Vp3\u002FVp4 or CNLC Ib-IIa with high-risk recurrence factors). Eligible subjects providing written informed consent will receive study treatment. The primary endpoint is MPR rate.",[27,28,29,30,31],"Hepatocellular Carcinoma","Immunotherapy","Preoperative","PD-1","CTLA-4","NOT_YET_RECRUITING","2025-08-13",{"date":35,"type":36},"2025-08-20","ACTUAL",{"date":38,"type":21},"2025-08-11",{"date":40,"type":21},"2029-08-31",{"name":42,"class":43},"The First Affiliated Hospital with Nanjing Medical University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":44},"100547403","preoperative-oral-midazolam-to-postoperative-pain-relief-in-sleep-disturbance-or-anxiety-patients-with-colorectal-cancer-100547403","NCT06407518","Preoperative Oral Midazolam to Postoperative Pain Relief in Sleep Disturbance or Anxiety Patients With Colorectal Cancer","Effects of Preoperative Oral Mmidazolam on Postoperative Pain in Sleep Disturbance or Anxiety Patients Undergoing Laparoscopic Colorectal Cancer Resection- A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Study","POMPPR","Inclusion Criteria:\n\n* 1\\. Signed of informed consent voluntarily; 2. Native Chinese speaker; 3. Age 18-60 years old, male or female; 4. BMI 18-30 kg\u002Fm2; 5. American Society of Anesthesiologists (ASA) grade 1 or 2, New York Heart Association (NYHA) gradeⅠor Ⅱ; 6. Non-emergency laparoscopic colorectal cancer resection; 7. General anesthesia with tracheal intubation; 8. Sleep disturbance (the Insomnia Severity Index,ISI≥15 ) or Anxiety (Generalized Anxiety Disorder scale-7,GAD-7≥10 ) from admission to surgery.\n\nExclusion Criteria:\n\n* 1\\. Contraindications for Midazolam Oral Solution (According to the Instruction for Midazolam Oral Solution); 2. High risk of Obstructive Sleep Apnea Symptoms (Total score of STOP-Bang scale ≥3 points); 3. Suspected dementia (Total score of Mini-Mental State Examination (MMSE) according to years of education: 0 year≤19 points; 1\\~6 years≤22 points; above of 6 years≤26 points); 4. Severe depressive symptom within two weeks (Total score of Patient Health Questionnaire-9 (PHQ-9)≥15); 5. History of Neurological and Psychiatric diseases (According to the electronic medical record system); 6. History of Chronic Obstructive Pulmonary Disease (According to the electronic medical record system); 7. History of Heart Failure (According to the electronic medical record system); 8. Intestinal obstruction(The electronic medical record system records those who currently have any type of intestinal obstruction); 9. Liver and renal insufficiency; 10. Have taken opioids or drugs that act on the central nervous system within one week; 11. Take CYP3A4 isoenzyme inhibitors or inducers within one week (According to the Instruction for Midazolam Oral Solution); 12. Consume any alcoholic beverage within 24 hours; 13. Substance abusers (including alcohol, drugs or addictive substances); 14. Pregnant or lactating women.","60 Years",{"count":55,"type":21},280,[57],"NA","Previous studies have indicated a high incidence of sleep disturbances and anxiety symptoms in individuals with colorectal cancers prior to undergoing surgery, leading to worsened postoperative pain, slower recovery, and higher risk of chronic pain. The enhancement of sleep quality is intricately linked to reducing stress. Preoperative drugs that combine hypnosis and anti-anxiety have not been studied in colorectal cancer patients. Midazolam oral solution is safe and effective for short-term hypnotic and anti-anxiety effects in clinical preoperative settings. In the current randomized controlled clinical trial, 280 patients experiencing sleep disturbance or anxiety prior to colorectal cancer surgery will receive midazolam solution to assess its potential efficacy in reducing postoperative pain, expediting recovery, and decreasing the likelihood of chronic pain. Additionally, the study aims to explore the potential connections between midazolam administration and reductions in stress and inflammation.",[29,60,61,62,63],"Sleep Disturbance","Anxiety","Midazolam","Pain, Postoperative",[65,66,67,68,69,70],"preoperative","oral midazolam","sleep disturbance","anxiety","postoperative pain","colorectal cancer","RECRUITING","2025-04-03",{"date":74,"type":36},"2025-04-06",{"date":76,"type":36},"2024-07-24",{"date":78,"type":21},"2025-12",{"name":80,"class":43},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":44},"100486392","phase-3-camrelizumab-combined-with-apatinib-mesylate-and-tace-in-the-perioperative-treatment-of-hepatocellular-carcinoma-100486392","NCT05613478","Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma","Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma: a Randomized, Open-label, Parallel, Multicenter Trial","Inclusion Criteria:\n\n* Volunteer to participate in this study and sign an informed consent form.\n* Age ≥18 years old, no gender limit.\n* Hepatocellular carcinoma confirmed by histopathology, cytology or imaging.\n* CNLC stage Ib (single tumor with diameter ≥8 cm)\u002FIIa\u002FIIb\u002FIIIa hepatocellular carcinoma, except for CNLC IIIa hepatocellular carcinoma combined with main portal vein tumor thrombus；multiple hepatocellular carcinoma was allowed to be treated with surgical excision combined with intraoperative ablation.\n* Child-Pugh score: A grade (≤6 points).\n* ECOG PS score: 0-1 points.\n\nExclusion Criteria:\n\n* Known intrahepatic cholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and fibrolamellar cell carcinoma; have other active malignancies other than HCC within 5 years or at the same time.\n* Currently accompanied by interstitial pneumonia or interstitial lung disease.\n* Existence of active autoimmune disease or history of autoimmune disease and may relapse.\n* Patients with active infection, unexplained fever ≥38.5℃ within 1 week before randomization, or baseline white blood cell count \\>15\\*10\\^9\u002FL.\n* Patients with congenital or acquired immune deficiencies (such as HIV-infected persons).\n* Those who are known to be allergic to any monoclonal antibodies, anti-angiogenesis targeted drugs or excipients.",{"count":89,"type":21},130,[91],"PHASE3","Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a curable and effective method. However, the recurrence rate is as high as 50%\\~70% in 5 years after surgery. Perioperative treatment with immunotherapy combined with target therapy is expected to improve the patient's prognosis. This study aims to evaluate the efficacy, safety and tolerability of camrelizumab combined with apatinib mesylate in the perioperative period of resectable hepatocellular carcinoma. The primary purpose of this study is to evaluate 2 year event-free survival（2y-EFS） of camrelizumab combined with apatinib mesylate in the perioperative period of hepatocellular carcinoma (CNLC Ib-IIIa). The secondary research purpose is to evaluate the R0 resection rate, the rate of subjects with major pathological response, the rate of subjects with pathological complete response, event-free survival (EFS) and overall survival of camrelizumab combined with apatinib mesylate in the perioperative period of resectable hepatocellular carcinoma. The safety and tolerability is also evaluated.",[27,28,29],"2024-12-30",{"date":96,"type":36},"2024-12-31",{"date":98,"type":36},"2023-01-31",{"date":100,"type":21},"2027-11-01",{"name":42,"class":43},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":44},"100563809","pre-operative-phentolamine-vs-intraoperative-esmolol-efficacy-for-hypotensive-anesthesia-in-functional-endoscopic-sinus-surgery-100563809","NCT06620991","Pre-operative Phentolamine Vs Intraoperative Esmolol Efficacy for Hypotensive Anesthesia in Functional Endoscopic Sinus Surgery","Inclusion Criteria:\n\n* Age from 21 to 50 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status I-II.\n\nExclusion Criteria:\n\n* Patients with a medical condition that contraindicated hypotensive anesthesia, such as peripheral vascular disease, cerebrovascular stroke, carotid artery stenosis, previous myocardial infarction, ischemic heart disease, congestive heart failure, limb ischemia, uncontrolled hypertension and raised intracranial tension\n* Renal disease, liver dysfunction, pregnancy.\n* Patients on hypnotic or narcotic analgesic.\n* History of alcohol or drug abuse.\n* History of allergic reaction to any drug used in this study.\n* Bleeding diathesis.\n* Previous nasal surgery.\n* Patients on Non-steroidal anti-inflammatory drugs (NSAIDs).\n* Patients with peripheral vascular disease.","21 Years","50 Years",{"count":111,"type":21},60,[57],"The aim of this study is to evaluate the efficacy of intra-operative phentolamine vs intraoperative esmolol for hypotensive anesthesia in functional endoscopic sinus surgery.",[29,115,116,117,118,119],"Phentolamine","Intraoperative","Esmolol","Hypotensive Anesthesia","Functional Endoscopic Sinus Surgery","2024-09-29",{"date":122,"type":36},"2024-10-01",{"date":124,"type":21},"2024-10-10",{"date":126,"type":21},"2025-04-01",{"name":128,"class":43},"Ain Shams University"]